Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis (“MS”), a third indication for the drug candidate. The Company will collaborate with the Cleveland Clinic through a new consulting agreement.

“Synaptogenix is excited to work with this internationally recognized team of experts. A clinical trial focused on both safety and efficacy is the priority of the collaboration. Advancing our clinical development plans through partnership has been a strategic focus over the past year and will continue to be a key focus going forward. We are very pleased that we’ve been able to partner with world leading institutions on endeavors such as this collaboration with Cleveland Clinic for MS and our previously announced Fragile X partnership with Nemours A. I. Dupont,” stated Dr. Alan Tuchman, CEO of Synaptogenix, Inc.

“Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical benefit from Bryostatin-1.  Elimination of synapses in MS patients, like those lost in AD, has not been addressed by currently available drug strategies. Through its synaptogenic, restorative mechanisms of action, we believe that Bryostatin-1 is uniquely positioned to target synaptic loss and cognitive dysfunction in MS, and potentially other aspects of the disease such as inflammation and demyelination. We will work with the Cleveland Clinic to finalize a protocol as soon as possible with the goal of moving towards a clinical trial soon thereafter,” stated Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine